ERBB2 and non-small cell lung carcinoma: Taken together, the TRAEMOS trial (T-DM1 and osimertinib) represents a pioneering effort in investigating the synergistic potential of T-DM1 and osimertinib for patients with EGFRm+ NSCLC exhibiting HER2 overexpression upon osimertinib resistance.